DexCom Inc. (NASDAQ:DXCM) shares saw an uptick in trading volume on Friday . 1,640,305 shares were traded during trading, an increase of 53% from the previous session’s volume of 1,068,741 shares.The stock last traded at $87.98 and had previously closed at $84.63.

A number of equities analysts have recently commented on DXCM shares. Jefferies Group reaffirmed a “positive” rating on shares of DexCom in a report on Friday. Leerink Swann reaffirmed an “outperform” rating and issued a $90.00 target price on shares of DexCom in a report on Wednesday. BTIG Research reaffirmed a “buy” rating and issued a $92.00 target price on shares of DexCom in a report on Tuesday, July 19th. Zacks Investment Research raised shares of DexCom from a “sell” rating to a “hold” rating in a report on Tuesday, July 19th. Finally, Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $93.00 target price on shares of DexCom in a report on Friday, July 15th. Three investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $94.62.

The company has a 50 day moving average of $76.95 and a 200 day moving average of $68.80. The company’s market cap is $7.33 billion.

DexCom (NASDAQ:DXCM) last released its earnings results on Wednesday, April 27th. The medical device company reported ($0.23) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by $0.03. During the same period in the prior year, the business posted ($0.17) EPS. The firm earned $116.20 million during the quarter, compared to the consensus estimate of $110.37 million. The company’s revenue was up 59.6% on a year-over-year basis. Equities research analysts predict that DexCom Inc. will post ($0.35) earnings per share for the current fiscal year.

In related news, EVP Richard Doubleday sold 1,666 shares of the company’s stock in a transaction that occurred on Monday, April 25th. The stock was sold at an average price of $69.15, for a total transaction of $115,203.90. Following the sale, the executive vice president now directly owns 94,900 shares of the company’s stock, valued at approximately $6,562,335. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Jeffrey Moy sold 12,843 shares of the company’s stock in a transaction that occurred on Tuesday, July 19th. The shares were sold at an average price of $83.78, for a total value of $1,075,986.54. The disclosure for this sale can be found here.

Other large investors have recently bought and sold shares of the company. Nicholas Co. Inc. WI raised its stake in DexCom by 26.7% in the fourth quarter. Nicholas Co. Inc. WI now owns 19,640 shares of the medical device company’s stock valued at $1,608,000 after buying an additional 4,140 shares in the last quarter. Morgan Stanley raised its stake in DexCom by 0.6% in the fourth quarter. Morgan Stanley now owns 1,268,992 shares of the medical device company’s stock valued at $103,930,000 after buying an additional 7,662 shares in the last quarter. California Public Employees Retirement System raised its stake in DexCom by 5.9% in the fourth quarter. California Public Employees Retirement System now owns 138,400 shares of the medical device company’s stock valued at $11,335,000 after buying an additional 7,700 shares in the last quarter. Principal Financial Group Inc. raised its stake in DexCom by 13.2% in the fourth quarter. Principal Financial Group Inc. now owns 79,782 shares of the medical device company’s stock valued at $6,534,000 after buying an additional 9,277 shares in the last quarter. Finally, I.G. Investment Management LTD. raised its stake in DexCom by 149.7% in the fourth quarter. I.G. Investment Management LTD. now owns 23,852 shares of the medical device company’s stock valued at $1,953,000 after buying an additional 14,300 shares in the last quarter.

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.